|
2008 Election Candidates The following individuals were elected to the Board of Directors in the 2008 elections. They will begin their terms following the 6th ISSCR Annual Meeting, June 11-14, 2008, Philadelphia, PA USA. We thank board members who will finish their terms for their contributions over the last few years and welcome the new and returning members of the Board of Directors. A very warm welcome is extended to Dr. Elaine Fuchs, who will take the position of ISSCR vice president this year, leading to her presidency in 2010-2011. Vice President
New Board Member Appointments
Board Member Reappointments
The Election for Positions on the ISSCR Board of Directors Election of Vice President Election of Board of Directors ISSCR Leadership 2008 Nominating Committee Review the 2008 Election Page. Candidate Biographies Vice President Elaine Fuchs Fuchs received her BS in Chemistry from U of Illinois, Champaign-Urbana in 1972 and her Ph.D. in Biochemistry from Princeton U in 1977. She was a Damon Runyon Postdoctoral fellow with H. Green at MIT, until 1980, when she joined the faculty at the U. of Chicago as an Asst. Prof. in Biochemistry. When she accepted a position at Rockefeller, Fuchs was the Amgen Professor in Molecular Genetics & Cell Biology. Her many awards and honors include the Presidential Young Investigator Award, the Richard Lounsbery Award from the National Academy of Sciences, the Novartis-Drew Award for Biomedical Research, the Dickson Prize in Medicine, the FASEB Award for Scientific Excellence and the Beering Award. for outstanding achievement in biomedical science. She is a member of the National Academy of Sciences, the Institute of Medicine of the National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society, and a fellow of the American Association for Microbiology and the American Association for the Advancement of Science. She holds honorary doctorates from Mt. Sinai/New York U. School of Medicine and from the U of Illinois, Champaign-Urbana. Fuchs is also a past President of the American Society of Cell Biology and current President of the Harvey Society. She has served on numerous national and international committees, including NAS Council, Scientific Advisory Council to the NIH Director, Board of Directors of the Damon Runyon Cancer Foundation, and Scientific Advisory Boards of the Whitehead Institute, CBRI at Harvard, and the Riken Institute for Developmental Biology. She is presently an Editor of the J. Cell Biology, and on the Editorial Boards of Cell, Cell Stem Cell, Genes & Development and Developmental Cell. New Board Member Appointments Margaret Buckingham Margaret Buckingham’s laboratory works on the stem cells of skeletal muscle and how their survival and entry into the myogenic programme are regulated by Pax genes, both in the embryo and the adult. They are also interested in cardiogenesis, notably in the origin and contribution of the second heart field and corresponding second myocardial cell lineage, during the formation of the mammalian heart. Daniel Marshak Dr. Marshak received his B.A. from Harvard University, Cambridge, Massachusetts, in Biochemistry & Molecular Biology, and his Ph.D. from The Rockefeller University, New York City, in Biochemistry & Cell Biology. He did postdoctoral research in Pharmacology at Vanderbilt University School of Medicine, Nashville, Tennessee, and at the National Institutes of Health, Bethesda, Maryland. Dr. Marshak has received several awards for scientific and academic achievements. He is also an inventor on six issued U.S. patents. Dr. Marshak has extensive research experience in the growth control of human cells. Dr. Marshak is author of more than 100 scientific publications, including one textbook, and he has been editor of five monographs. The most recent monograph, Stem Cell Biology, was published in 2001 by The Cold Spring Harbor Laboratory Press. Shinya Yamanaka Board Member Reappointments Markus Grompe His research has focussed on the use of in vivo selection to enhance gene and cell therapy, particularly stem cell therapy. The two model diseases being studied are hereditary tyrosinemia type 1, a childhood liver disease and Fanconi Anemia (FA), a blood disorder. In 1996, his laboratory showed that gene therapy in combination in vivo selection could be used to replace > 90% of cells in a diseased mouse liver. Since then, his work has focussed on the biology of intra- and extrahepatic liver stem cells and their use in therapeutic liver repopulation. Recently, his group developed a method to replace the cells of mouse livers with human hepatocytes. The Fanconi anemia pathway is involved in the maintenance of genomic stability and stem cell integrity in mammals. The Grompe Lab cloned a novel Fanconi Anemia gene, FANCD2, which has been shown to link the Fanconi Anemia pathway to BRCA1 and BRCA2, genes involved in familial breast cancer. Preclinical gene therapy experiments in murine models of FA have been used to demonstrate in vivo selection at the level of hematopoietic stem cells. Recently, the Grompe lab has discovered small molecules to prevent solid tumors in this disease. He is a recipient of the E. Mead Johnson award for pediatric research and the Merit Award of the Fanconi Anemia Research Foundation. He is involved in the clinical care of patients with genetic diseases as well as scientific investigation. In 2004 he became the first director of the newly founded Oregon Stem Cell Center (http://www.ohsu.edu/oscc/). His research has focussed on the use of in vivo selection to enhance gene and cell therapy, particularly stem cell therapy. The two model diseases being studied are hereditary tyrosinemia type 1, a childhood liver disease and Fanconi Anemia (FA), a blood disorder. In 1996, his laboratory showed that gene therapy in combination in vivo selection could be used to replace > 90% of cells in a diseased mouse liver. Since then, his work has focussed on the biology of intra- and extrahepatic liver stem cells and their use in therapeutic liver repopulation. Recently, his group developed a method to replace the cells of mouse livers with human hepatocytes. The Fanconi anemia pathway is involved in the maintenance of genomic stability and stem cell integrity in mammals. The Grompe Lab cloned a novel Fanconi Anemia gene, FANCD2, which has been shown to link the Fanconi Anemia pathway to BRCA1 and BRCA2, genes involved in familial breast cancer. Preclinical gene therapy experiments in murine models of FA have been used to demonstrate in vivo selection at the level of hematopoietic stem cells. Recently, the Grompe lab has discovered small molecules to prevent solid tumors in this disease. Olle Lindvall He has received numerous Prizes and Awards. Dr. Lindvall is since 2004 member of the Board of the International Society for Stem Cell Research, and since 2005 member of the Board of Reviewing Editors for SCIENCE and member of the Scientific Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research. Since 1983 Dr. Lindvall has headed the clinical neurotransplantation program in Lund. This program has pioneered cell replacement strategies and been the first to show proof-of-principle, i.e., that transplanted neurons can survive, grow, restore transmitter release, become functionally integrated, and give rise to clinically measurable improvements in the diseased, 50-60 year old human brain. Current research interests in Dr. Lindvall’s laboratory are the development of stem cell-based approaches for cell replacement in Parkinson’s disease and stroke, and of gene therapeutic strategies for neuroprotection and neuroregeneration in Parkinson’s disease. Much focus is on the role and possible therapeutic relevance of neurogenesis from the adult brain’s own neural stem cells in stroke and epilepsy. Sir Ian Wilmut Review the 2008 Election Page. Updated: April 7, 2008 |
|||||||
| Disclaimers | Privacy Information | Contact Us | Site Map |
Elaine Fuchs is presently Rebecca C. Lancefield Professor, Head of the Laboratory of Mammalian Cell Biology and Development at The Rockefeller University, where she has been since leaving the U. of Chicago in 2002. She has been an Investigator of the Howard Hughes Medical Institute since 1988. Fuchs is a world leader in the field of skin stem cells, their biology and associated human genetic disorders, which include skin cancers and life-threatening genetic syndromes such as blistering skin disorders. From nearly the beginning of her scientific career, Fuchs focused on the molecular mechanisms that underlie the development and differentiation of the epidermis and hair follicles from stem cells. Throughout her studies, she has continually used the basic biology that she uncovered to elucidate how perturbations of these mechanisms result in disease. She has systematically applied molecular and genetic approaches to these problems, having conceived and applied reverse genetic strategies to elucidate the functions and genetic basis of the first intermediate filament disorders, a skin tumor due to excessive Wnt/β-catenin signaling, and roles for loss of α-catenin and TGFβ receptor signaling in squamous cell carcinomas and tumor invasion. Her group devised creative approaches for identifying, isolating and characterizing the multipotent stem cells from skin, determined a number of underlying features of how stem cells receive external signals, become activated to change their program of transcription and select specific fates, and to alter their cytoskeletal-adhesive networks to migrate and differentiate. In facing the problem of progressing from a stem cell to tissues, Fuchs’ multifaceted approaches and developing paradigms at the interface of basic and medical sciences have greatly our understanding of stem cells in other tissues and organs of the body. She has published more than 250 papers, mostly in high profile scientific and medical journals. 
Professor at the Pasteur Institute, Director of Research in the French C.N.R.S., Member of the French Academy of Sciences.
Daniel R. Marshak, Ph.D. is Vice President and Chief Scientific Officer for PerkinElmer, Inc. (NYSE:PKI). Dr. Marshak is responsible for setting the strategic direction of PerkinElmer's research and development functions, and helping drive its growth strategies in the emerging areas of personalized medicine and predictive diagnostics. 
Shinya Yamanaka received his M.D. from Kobe University in 1987 and his Ph.D. from Osaka City University in 1993. From 1987 to 1989 he was a resident at the National Osaka Hospital. He spent the period from 1993 to 1996 as a postdoctoral fellow in the Gladstone Institute of Cardiovascular Disease, San Francisco. He returned to Osaka City University Medical School to take an assistant professor position in 1996, and was appointed as an associate professor at Nara Institute of Science and Technology in 1999, where he became a full professor in 2003. He moved on to take up his current position as a professor in Kyoto University in 2004. In addition, he received an appointment as a visiting scientist at the Gladstone Institute in 2007. 
Dr. Grompe received his medical degree (Dr. med.) in 1983 at the University of Ulm Medical School in Germany. His interest in Human Genetics started with a one year research project abroad during medical school. From 1984-1987 Dr. Grompe was trained in Pediatrics at Oregon Health Sciences University in Portland, Oregon, USA and then moved to Baylor College of Medicine in Houston, Texas. There he was a fellow sponsored by the Pediatric Scientist Training Program in the Institute for Molecular Genetics from 1987-1991 and worked on gene therapy for inherited diseases, particularly metabolic liver disorders. In 1991, Dr. Grompe joined the faculty at Oregon Health & Sciences University and he is currently Professor in the Departments of Molecular and Medical Genetics and Pediatrics (
Dr. Olle Lindvall is Professor of Clinical Neurology and Chairman of the Division of Neurology at the University Hospital, Lund, Sweden. He has served as Chairman of the Swedish Movement Disorder Society 1995-1998, Vice-Dean of the Medical Faculty at the University of Lund 1997-1999, elected member of the Board of the Swedish Research Council (medical division) 2001-2006, clinical coordinator in EU-sponsored integrated project EuroStemCell 2003-2007, and Chairman of the Steering Committee for Nordic Centers of Excellence in Molecular Medicine 2003-2007. 
Sir Ian Wilmut, Ph.D., D.Sc., is the chair of reproductive science at the Centre for Reproductive Biology in the new Queen's Medical Research Institute. He was previously head of the Department of Gene Function and Development at the Roslin Institute where his group produced Dolly the sheep, the first clone from an adult animal, and went on to use the new methods to introduce precise genetic change into livestock. He obtained a B.Sc. in agricultural science at the University of Nottingham before studying at the University of Cambridge. He is an Honorary Professor in Division of Biological Sciences, University of Edinburgh.   |